![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, January 15, 2014 6:30:56 AM
Many potential catalysts lining up for NNVC SP increase now, I think.
Week of JP Morgan Healthcare conference in San Fran usually causes run up in SP of BioTech stocks.
Dr. Seymour to present at EBD BioTech Showcase conference in San Fran with potential announcements of one or more of the following.
Could announce start of GLP Tox study
- if so, greatly betters chance of FluCide clinical studies this year.
Could announce progress on cGMP pilot manufacturing for clinical study materials.
- if so, checks off one more item for FluCide clinical studies this year.
Could announce scheduling and date set for FluCide efficacy studies in PHE and/or Lovelace.
- if so, also increases odds for Flucide clinical studies this year.
Dr. Seymour and other officers presence at the BioTech Showcase also offers opportunities for networking for potential partnerships with larger companies attending the JPM HC conf - both in San Francisco at the same time.
So traders may just be looking at this as a time with better odds for a nice jump in share price over a short time period...~ robi-1-kenobi
NanoViricides, Inc. should request and should be granted designation of breakthrough therapy FAST TRACK (good for flying horses) by the FDA once the GLP evidence/report on "tox studies" is presented by Bioanalytical Systems, Inc., Indiana. We should see an explosion in pps, or KaBOOM. around first quarter of 2015!!! You ain't seen nothing yet!!!...but we will this year and next...and the following years!!! Think of the possibilities...it is transformational nanotechnology.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM